July 7th 2024
The combination of englumafusp alfa and glofitamab showed a BOR of 67.0% and CR rate of 57.0% in second-line settings. In third-line settings, the BOR was 65.7% and the CR rate was 52.8%.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
CAR T Cells Shown Effective Without Increased Risk of CRS or ICANS in CNS-Involved LBCL
April 25th 2022Looking at 4 CAR T-cell agents for the treatment of large B-cell lymphoma, a systematic review and analysis showed that these therapies do not appear to increase the risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome.
Read More
Long-Term OS Data for Axi-Cel Hint Short-Term EFS is a Surrogate End Point for R/R LBCL
April 24th 2022According to a long-term analysis of the ZUMA-1 study, the overall survival rate yielded by axicabtagene ciloleucel may support 1- and 2-year event-free survival as a surrogate end point in relapsed/refractory large B-cell lymphoma.
Read More
TakeAim Lymphoma Study Evaluating Emavusertib Pauses Enrollment of Patients With B-cell Malignancies
April 11th 2022With a voluntary partial clinical hold in place, patients who were already enrolled to the TakeAim Lymphoma study and deriving benefit from emavusertib can continue treatment at the dose of 300 mg twice daily or lower.
Read More
T-Cell Attributes of Axi-cel Correlate With Outcomes in Large B-Cell Lymphoma
April 11th 2022CCR7-positive and CD45RA-positive T cells that expressed CD27 and CD28 appear to be associated with all efficacy metrics, including durability or response, according to an analysis of the ZUMA-7 clinical trial.
Read More
FDA Discourages Marketing Authorization for Zandelisib in Patients With FL or MZL
March 25th 2022The FDA discouraged marketing authorization for zandelisib based data from the phase 2 TIDAL study which examined the PI3K inhibitor in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma.
Read More
Bortezomib Shows Survival Benefit in Children With T-Cell Lymphoblastic Lymphoma
March 14th 2022The AALL1231 trial of bortezomib showed survival benefit for children with T-cell lymphoblastic lymphoma and significantly reduced need for cranial radiotherapy in patients with T-cell acute lymphoblastic leukemia.
Read More
Tisagenlecleucel Not Superior to SOC as 2L Treatment for Aggressive B-cell Lymphoma
March 10th 2022Significantly longer event-free survival was not demonstrated with tisagenlecleucel in the second-line setting when compared to standard-of-care second-line therapy in patients with refractory or early relapsed aggressive B-cell lymphoma.
Read More
FDA Grants Priority Review to Liso-Cel for Adults With Relapsed/Refractory LBCL
February 17th 2022The FDA will conduct a speedy review of the supplemental biologics license application for lisocabtagene maraleucel as second-line treatment for adult patients with relapsed or refractory large B-cell lymphoma.
Read More